13F portfolio / Investment manager
RTW Investments
Roderick Wong (managing partner, CIO)
The firm is based in New York, NY, according to its SEC filings.
Its earliest 13F holdings report on SEC EDGAR was filed in February 2015.
SEC Form ADV lists Roderick Wong as managing partner and chief investment officer.
The 13F shows long US-listed stock and option positions only. It leaves out short positions, cash, bonds and most non-US holdings.
- Reported 13F value
- $11.7B
- Positions
- 84
- Est. 1-yearEstimate
- +25.6%SPY +15.7%
- Est. 3-year, annualizedEstimate
- —SPY +22.8%
As of Jun 30, 2026 · filed Aug 14, 2026
Holdings
9 new · 24 added · 8 trimmed · 43 unchanged · 13 sold out
| 1 | MDGL on Yahoo Finance (opens in a new tab) | Madrigal Pharmaceuticals IncCOM | 9.1% | $1.1B | 1,993,687 | Unchanged | $225.81* | $447.74 | +98.3% |
| 2 | ARGX on Yahoo Finance (opens in a new tab) | Argenx SeSPONSORED ADR | 5.6% | $658M | 709,446 | Unchanged | $516.35* | $816.79 | +58.2% |
| 3 | PTCT on Yahoo Finance (opens in a new tab) | PTC Therapeutics IncCOM | 5.4% | $632M | 7,746,415 | Unchanged | $31.70* | $59.14 | +86.5% |
| 4 | PTGX on Yahoo Finance (opens in a new tab) | Protagonist Therapeutics IncCOM | 5.3% | $620M | 5,061,175 | Unchanged | $20.07* | $127.72 | +536.5% |
| 5 | CGON on Yahoo Finance (opens in a new tab) | Cg Oncology IncCOM | 5.2% | $605M | 8,514,590 | Added +21.9% | $53.55 | $59.76 | +11.6% |
| 6 | INSM on Yahoo Finance (opens in a new tab) | Insmed IncCOM PAR $.01 | 4.4% | $516M | 4,842,880 | Unchanged | $87.43* | $96.60 | +10.5% |
| 7 | TNGX on Yahoo Finance (opens in a new tab) | Tango Therapeutics IncCOM | 3.7% | $435M | 13,900,620 | Added +4.5% | $13.82 | $22.19 | +60.6% |
| 8 | SYRE on Yahoo Finance (opens in a new tab) | Spyre Therapeutics IncCOM NEW | 3.2% | $377M | 4,251,996 | Added +1.9% | $22.63 | $79.50 | +251.3% |
| 9 | CELC on Yahoo Finance (opens in a new tab) | Celcuity IncCOM | 3.0% | $346M | 3,304,903 | Added +8.7% | $105.08 | $55.10 | -47.6% |
| 10 | ERAS on Yahoo Finance (opens in a new tab) | Erasca IncCOM | 2.8% | $329M | 17,946,754 | Added +11.1% | $11.99 | $13.47 | +12.3% |
| 11 | RDNT on Yahoo Finance (opens in a new tab) | Radnet IncCOM | 2.6% | $299M | 4,846,958 | Added +13.1% | $56.22 | $68.57 | +22.0% |
| 12 | ORKA on Yahoo Finance (opens in a new tab) | Oruka Therapeutics IncCOM | 2.6% | $299M | 3,139,030 | Added +52.5% | $38.14 | $71.01 | +86.2% |
| 13 | NTRA on Yahoo Finance (opens in a new tab) | Natera IncCOM | 2.3% | $271M | 1,000,000 | Trimmed -20.0% | $51.43* | $391.99 | +662.1% |
| 14 | RARE on Yahoo Finance (opens in a new tab) | Ultragenyx Pharmaceutical InCOM | 2.2% | $260M | 7,796,895 | Added +113.7% | $28.33* | $14.69 | -48.2% |
| 15 | IRTC on Yahoo Finance (opens in a new tab) | Irhythm Holdings IncCOM | 2.2% | $260M | 2,182,631 | Added +30.8% | $155.51 | $110.21 | -29.1% |
| 16 | CYTK on Yahoo Finance (opens in a new tab) | Cytokinetics IncCOM NEW | 2.1% | $244M | 2,862,003 | Added +5.2% | $36.95* | $62.22 | +68.4% |
| 17 | KLRA on Yahoo Finance (opens in a new tab) | Kailera Therapeutics IncCOMMON STOCK | 2.0% | $237M | 10,776,820 | New | $21.98 | $11.49 | -47.7% |
| 18 | ESTA on Yahoo Finance (opens in a new tab) | Establishment Labs Hldgs IncCOM | 1.9% | $228M | 2,655,695 | Unchanged | $51.67* | $59.58 | +15.3% |
| 19 | GH on Yahoo Finance (opens in a new tab) | Guardant Health IncCOM | 1.9% | $222M | 1,481,033 | Unchanged | $48.77 | $159.15 | +226.3% |
| 20 | NBIX on Yahoo Finance (opens in a new tab) | Neurocrine Biosciences IncCOM | 1.8% | $214M | 1,267,925 | Added +19.4% | $120.15 | $136.24 | +13.4% |
| 21 | TARS on Yahoo Finance (opens in a new tab) | Tarsus Pharmaceuticals IncCOM | 1.8% | $211M | 3,357,059 | Unchanged | $21.87* | $68.53 | +213.3% |
| 22 | STOK on Yahoo Finance (opens in a new tab) | Stoke Therapeutics IncCOM | 1.6% | $184M | 5,623,525 | Unchanged | $8.38* | $24.20 | +189.0% |
| 23 | QURE on Yahoo Finance (opens in a new tab) | Uniqure NVSHS | 1.5% | $182M | 3,941,572 | Added +52.4% | $17.52 | $22.00 | +25.6% |
| 24 | ACAD on Yahoo Finance (opens in a new tab) | Acadia Pharmaceuticals IncCOM | 1.5% | $181M | 7,144,524 | Unchanged | $24.62* | $19.18 | -22.1% |
| 25 | RGEN on Yahoo Finance (opens in a new tab) | Repligen CorpCOM | 1.4% | $169M | 1,240,637 | Added +2.9% | $153.75 | $173.41 | +12.8% |
| 26 | URGN on Yahoo Finance (opens in a new tab) | Urogen Pharma LtdCOM | 1.4% | $167M | 4,543,895 | Unchanged | $14.34* | $34.63 | +141.5% |
| 27 | GHRS on Yahoo Finance (opens in a new tab) | Gh Research PLCORDINARY SHARES | 1.4% | $160M | 5,933,815 | Unchanged | $10.82* | $18.08 | +67.1% |
| 28 | IMCR on Yahoo Finance (opens in a new tab) | Immunocore Hldgs PLCADS | 1.3% | $155M | 4,869,798 | Unchanged | $53.26* | $30.01 | -43.7% |
| 29 | CMPS on Yahoo Finance (opens in a new tab) | Compass Pathways PLCSPONSORED ADS | 1.3% | $151M | 10,700,974 | Added +0.6% | $4.76 | $10.91 | +129.0% |
| 30 | IMTX on Yahoo Finance (opens in a new tab) | Immatics N.VSHS | 1.1% | $131M | 12,946,176 | Added +0.6% | $10.06* | $6.75 | -32.9% |
| 31 | ZLAB on Yahoo Finance (opens in a new tab) | Zai Lab LtdADR | 1.1% | $125M | 6,574,032 | Unchanged | $25.69 | $23.64 | -8.0% |
| 32 | IMVT on Yahoo Finance (opens in a new tab) | Immunovant IncCOM | 1.0% | $122M | 3,177,849 | Unchanged | $22.30 | $26.54 | +19.0% |
| 33 | BLTE on Yahoo Finance (opens in a new tab) | Belite Bio IncSPONSORED ADS | 0.9% | $110M | 715,332 | Unchanged | $95.37 | $143.41 | +50.4% |
| 34 | XNCR on Yahoo Finance (opens in a new tab) | Xencor IncCOM | 0.9% | $109M | 6,777,461 | Unchanged | $13.91 | $22.91 | +64.7% |
| 35 | TSHA on Yahoo Finance (opens in a new tab) | Taysha Gene Therapies IncCOM SHS | 0.8% | $92M | 13,560,258 | Trimmed -0.9% | $2.30* | $3.63 | +57.6% |
| 36 | COGT on Yahoo Finance (opens in a new tab) | Cogent Biosciences IncCOM | 0.8% | $89M | 2,309,021 | Trimmed -57.7% | $20.68 | $29.39 | +42.1% |
| 37 | ALKS on Yahoo Finance (opens in a new tab) | Alkermes PLCSHS | 0.7% | $88M | 1,672,356 | Unchanged | $27.15* | $40.56 | +49.4% |
| 38 | GPCR on Yahoo Finance (opens in a new tab) | Structure Therapeutics IncSPONSORED ADS | 0.7% | $86M | 1,607,507 | New | $44.24 | $21.04 | -52.4% |
| 39 | REPL on Yahoo Finance (opens in a new tab) | Replimune Group IncCOM | 0.7% | $82M | 7,411,581 | Added +0.7% | $7.45 | $10.98 | +47.5% |
| 40 | CSTL on Yahoo Finance (opens in a new tab) | Castle Biosciences IncCOM | 0.6% | $66M | 2,778,335 | Added +0.7% | $32.29 | $31.95 | -1.0% |
| 41 | CADL on Yahoo Finance (opens in a new tab) | Candel Therapeutics IncCOM | 0.6% | $66M | 6,422,018 | Unchanged | $5.44 | $8.34 | +53.3% |
| 42 | RCKT on Yahoo Finance (opens in a new tab) | Rocket Pharmaceuticals IncCOM | 0.5% | $60M | 17,687,772 | Unchanged | $19.60* | $2.24 | -88.6% |
| 43 | KOD on Yahoo Finance (opens in a new tab) | Kodiak Sciences IncCOM | 0.5% | $58M | 1,487,934 | Unchanged | $20.48 | $87.73 | +328.4% |
| 44 | AKTS on Yahoo Finance (opens in a new tab) | Aktis Oncology IncCOM | 0.4% | $51M | 1,592,043 | Unchanged | $19.42 | $15.01 | -22.7% |
| 45 | AXGN on Yahoo Finance (opens in a new tab) | Axogen IncCOM | 0.4% | $47M | 1,011,576 | New | $40.32 | $35.05 | -13.1% |
| 46 | DHR on Yahoo Finance (opens in a new tab) | Danaher Corp DelCOM | 0.4% | $44M | 230,000 | New | $180.89 | $229.01 | +26.6% |
| 47 | CGEM on Yahoo Finance (opens in a new tab) | Cullinan Therapeutics IncCOM | 0.4% | $43M | 2,364,347 | Added +38.6% | $18.52 | $13.19 | -28.8% |
| 48 | NGNE on Yahoo Finance (opens in a new tab) | Neurogene IncCOM | 0.4% | $43M | 1,362,456 | Unchanged | $34.49 | $23.59 | -31.6% |
| 49 | HNGE on Yahoo Finance (opens in a new tab) | Hinge Health IncCL A | 0.4% | $42M | 500,000 | Trimmed -74.1% | $42.77 | $99.42 | +132.5% |
| 50 | OBIO on Yahoo Finance (opens in a new tab) | Orchestra Biomed Hldgs IncCOM | 0.4% | $41M | 9,556,063 | Added +15.0% | $6.67* | $5.41 | -18.9% |
| 51 | SLDB on Yahoo Finance (opens in a new tab) | Solid Biosciences IncCOM NEW | 0.3% | $39M | 3,892,926 | New | $7.58 | $5.59 | -26.3% |
| 52 | SVRA on Yahoo Finance (opens in a new tab) | Savara IncCOM | 0.3% | $37M | 5,952,380 | Unchanged | $4.90 | $4.51 | -8.0% |
| 53 | AQST on Yahoo Finance (opens in a new tab) | Aquestive Therapeutics IncCOM | 0.3% | $31M | 7,426,471 | Unchanged | $4.28 | $3.84 | -10.4% |
| 54 | KYMR on Yahoo Finance (opens in a new tab) | Kymera Therapeutics IncCOM | 0.2% | $28M | 240,000 | Unchanged | $67.53 | $105.08 | +55.6% |
| 55 | VSTM on Yahoo Finance (opens in a new tab) | Verastem IncCOM NEW | 0.2% | $25M | 6,635,793 | Added +0.9% | $6.82 | $8.79 | +28.9% |
| 56 | DNTH on Yahoo Finance (opens in a new tab) | Dianthus Therapeutics IncCOM | 0.2% | $24M | 248,063 | Unchanged | $57.91 | $69.69 | +20.4% |
| 57 | BBNX on Yahoo Finance (opens in a new tab) | Beta Bionics IncCOM | 0.2% | $24M | 1,500,000 | Trimmed -25.0% | $18.64 | $16.84 | -9.7% |
| 58 | IPSC on Yahoo Finance (opens in a new tab) | Century Therapeutics IncCOM | 0.2% | $21M | 8,695,652 | Unchanged | $2.10 | $1.42 | -32.2% |
| 59 | EVMN on Yahoo Finance (opens in a new tab) | Evommune IncCOM SHS | 0.2% | $20M | 1,502,235 | Unchanged | $19.34 | $5.27 | -72.8% |
| 60 | BEAM on Yahoo Finance (opens in a new tab) | Beam Therapeutics IncCOM | 0.2% | $20M | 570,394 | Unchanged | $25.51 | $23.26 | -8.8% |
| 61 | DFTX on Yahoo Finance (opens in a new tab) | Definium Therapeutics IncCOM SHS | 0.2% | $19M | 400,000 | Added +33.3% | $18.90 | $32.20 | +70.3% |
| 62 | IDYA on Yahoo Finance (opens in a new tab) | Ideaya Biosciences IncCOM | 0.1% | $14M | 370,370 | New | $30.61 | $33.12 | +8.2% |
| 63 | — | Ataibeckley IncCOM SHS | 0.1% | $11M | 2,000,000 | Unchanged | — | — | — |
| 64 | MIST on Yahoo Finance (opens in a new tab) | Milestone Pharmaceuticals InCOM | 0.1% | $10M | 7,833,336 | Added +23.7% | $2.12* | $0.72 | -65.9% |
| 65 | OCGN on Yahoo Finance (opens in a new tab) | Ocugen IncCOM | 0.1% | $10M | 6,666,666 | Unchanged | $1.73 | $0.81 | -53.4% |
| 66 | TENX on Yahoo Finance (opens in a new tab) | Tenax Therapeutics IncCOM NEW | 0.1% | $10M | 696,570 | Added +88.1% | $9.39 | $1.40 | -85.0% |
| 67 | HTFL on Yahoo Finance (opens in a new tab) | Heartflow IncCOM | 0.1% | $9M | 295,000 | Trimmed -40.4% | $32.24 | $48.98 | +51.9% |
| 68 | FRNM on Yahoo Finance (opens in a new tab) | Perceptive Cap Solutions CorCL A ORD SHS | 0.1% | $8M | 742,500 | Unchanged | $10.07 | $11.83 | +17.4% |
| 69 | WVE on Yahoo Finance (opens in a new tab) | Wave Life Sciences LtdSHS | 0.1% | $8M | 1,350,000 | Unchanged | $7.37 | $3.11 | -57.9% |
| 70 | LRMR on Yahoo Finance (opens in a new tab) | Larimar Therapeutics IncCOM | 0.1% | $8M | 2,565,999 | Added +71.1% | $3.84 | $2.04 | -46.9% |
| 71 | LMRI on Yahoo Finance (opens in a new tab) | Lumexa Imaging Holdings IncCOM | 0.1% | $7M | 650,000 | Unchanged | $18.05 | $10.85 | -39.9% |
| 72 | ALLO on Yahoo Finance (opens in a new tab) | Allogene Therapeutics IncCOM | 0.1% | $7M | 3,250,000 | New | $2.20 | $1.32 | -39.9% |
| 73 | CBIO on Yahoo Finance (opens in a new tab) | Crescent Biopharma Inc.COM | 0.1% | $7M | 372,856 | Unchanged | $12.74 | $12.07 | -5.3% |
| 74 | FDMT on Yahoo Finance (opens in a new tab) | 4d Molecular Therapeutics InCOM | 0.1% | $6M | 475,737 | Unchanged | $10.14 | $12.28 | +21.1% |
| 75 | MAZE on Yahoo Finance (opens in a new tab) | Maze Therapeutics IncCOM | 0.1% | $6M | 212,000 | New | $26.21 | $27.24 | +3.9% |
| 76 | CAPR on Yahoo Finance (opens in a new tab) | Capricor Therapeutics IncCOM NEW | 0.1% | $6M | 250,000 | Unchanged | $13.06 | $6.73 | -48.5% |
| 77 | KLRS on Yahoo Finance (opens in a new tab) | Kalaris Therapeutics IncCOM | 0.0% | $5M | 1,300,000 | Unchanged | $6.39 | $2.24 | -65.0% |
| 78 | ABVX on Yahoo Finance (opens in a new tab) | Abivax SASPONSORED ADS | 0.0% | $4M | 26,400 | New | $113.18 | $87.77 | -22.4% |
| 79 | AVTX on Yahoo Finance (opens in a new tab) | Avalo Therapeutics IncCOM NEW | 0.0% | $3M | 175,000 | Trimmed -79.6% | $15.64 | $11.35 | -27.4% |
| 80 | MDLN on Yahoo Finance (opens in a new tab) | Medline IncCOM CL A | 0.0% | $3M | 70,000 | Unchanged | $42.23 | $36.44 | -13.7% |
| 81 | IRON on Yahoo Finance (opens in a new tab) | Disc Medicine IncCOM | 0.0% | $2M | 30,000 | Unchanged | $84.50 | $56.21 | -33.5% |
| 82 | IMA on Yahoo Finance (opens in a new tab) | Imagenebio IncCOM | 0.0% | $2M | 334,445 | Unchanged | $13.25 | $4.05 | -69.4% |
| 83 | XGN on Yahoo Finance (opens in a new tab) | Exagen IncCOM | 0.0% | $907K | 195,000 | Trimmed -50.7% | $2.79* | $7.72 | +176.5% |
| 84 | RCKT on Yahoo Finance (opens in a new tab) | Rocket Pharmaceuticals Inc*W EXP 09/02/202 | 0.0% | $1K | 350,000 | Unchanged | $19.60* | $2.24 | -88.6% |
Sold out since Q1 2026
- —Apogee Therapeutics Inc$234M at Q1 2026
- —Apellis Pharmaceuticals Inc$148M at Q1 2026
- ISRG on Yahoo Finance (opens in a new tab)Intuitive Surgical Inc$101M at Q1 2026
- —Centessa Pharmaceuticals PLC$82M at Q1 2026
- —Crinetics Pharmaceuticals In$53M at Q1 2026
- WAY on Yahoo Finance (opens in a new tab)Waystar Hldg Corp$39M at Q1 2026
- ARWR on Yahoo Finance (opens in a new tab)Arrowhead Pharmaceuticals In$37M at Q1 2026
- SYK on Yahoo Finance (opens in a new tab)Stryker Corporation$33M at Q1 2026
- CMPX on Yahoo Finance (opens in a new tab)Compass Therapeutics Inc$22M at Q1 2026
- FLGT on Yahoo Finance (opens in a new tab)Fulgent Genetics Inc$20M at Q1 2026
- JBIO on Yahoo Finance (opens in a new tab)Jade Biosciences Inc$8M at Q1 2026
- IVA on Yahoo Finance (opens in a new tab)Inventiva SA$7M at Q1 2026
- OMDA on Yahoo Finance (opens in a new tab)Omada Health Inc$3M at Q1 2026
Estimated, from reported holdings
Quarter by quarter
High-conviction buys (new positions at 3% or more of the portfolio) since Q3 2023: 0. Of 0 with six months of history, — beat the S&P 500 from the filing date.
Source: SEC Form 13F-HR 0001493215-26-000164, compared with the Q1 2026 report. 0 option rows are excluded from weights. Tickers map from CUSIP via OpenFIGI. Estimated returns weight each position’s next-quarter total return (Yahoo Finance adjusted closes) by its quarter-end value and assume no trades. Estimated cost averages daily adjusted closes in each quarter the share count rose, from Q3 2023 onward (* = held at the start of our data). Price is the latest close.
Important information
Form 13F data is delayed. Managers have up to 45 days after each calendar quarter to file, so holdings shown may have changed materially since the report date. 13F reports cover long positions in US-listed equities and certain other securities only; they exclude short positions, most non-US holdings, cash, bonds and private investments, and managers may request confidential treatment for some positions. Options rows are listed in filings but are not counted in the holdings and weights shown here.
Estimated holdings returns, estimated cost and high-conviction results are hypothetical calculations from quarter-end holdings and public prices, assuming no trades between reports. They are not the actual returns or costs of any fund or manager and do not reflect fees, trading, leverage, shorts or cash. Biographies are drawn from cited public sources. This page is for information only and is not individualized investment advice or a recommendation to buy or sell any security. Gulfstream Capital and its clients may hold positions in securities shown.